29th Apr 2016 11:52
LONDON (Alliance News) - AstraZeneca PLC on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion on the UK drugmaker's CAZ AVI antibiotic, recommending it for approval.
CAZ AVI has been developed to treat a broad range of antibiotic-resistant bacterial infections, AstraZeneca said.
The recommendation covers the intravenous use of the drug in treatment of adult patients with complicated intra-abdominal infection, complicated urinary tract infection and hospital-acquired pneumonia.
The drug has been jointly-developed by AstraZeneca and US firm Allergan. AstraZeneca holds the global rights to commercialise the product, with the exception of North America, where Allergan holds the rights.
AstraZeneca shares were up 1.6% to 4,021.50 pence.
Earlier in the day, the company reiterated its full-year guidance for 2016 at constant currency, as it said revenue rose 5% in the first quarter on a constant currency basis, driven by a significant increase in externalisation revenue
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca